Guselkumab

Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights

Retrieved on: 
Tuesday, October 3, 2023
Ixekizumab, Secukinumab, Amgen, NASA RealWorld-InWorld Engineering Design Challenge, MOA, TNF, Arthritis, Upadacitinib, Eli Lilly and Company, Risankizumab, Rheumatology, Patient, Psoriatic arthritis, Novartis, AbbVie, Algorithm, Physician, Need for Speed, Kwaku Amoa-Awuah, Safety, Guselkumab, Pharmaceutical industry, Apremilast

This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.

Key Points: 
  • This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.
  • Spherix Global Insights recently published its seventh annual Patient Chart Dynamix™: Triggers and Drivers in Psoriatic Arthritis, (previously RealWorld Dynamix: Switching in Psoriatic Arthritis).
  • Patients receiving TNFs are also provided an ample period of treatment in the first-line setting before considering a switch to an alternative therapy.
  • Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

Royalty Pharma Reports Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 8, 2023
Acceleration, Net, Pressure, University, Civil service commission, Astellas Pharma, Chronic lymphocytic leukemia, Vertex, Calendar, Aplastic anemia, DPP, GAAP, Leuprorelin, Sale, Ulcerative colitis, Psoriasis, Gilead, EBITDA, Acquisition, European Commission, Patient, Risk, Metastasis, Cystic fibrosis, Growth, Johnson & Johnson, California Miramar University, FDA, Sacituzumab govitecan, Regulation of tobacco by the U.S. Food and Drug Administration, Death, Food, Ivacaftor, Pfizer, Talazoparib, Bank, Video game, Music, Vaccine, Pharmaceutical industry, Real estate, Cryptocurrency, Berotralstat, Apalutamide, Nusinersen, Elexacaftor/tezacaftor/ivacaftor, Adjustment, Guselkumab, Ibrutinib

Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).

Key Points: 
  • Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
  • During the second quarter of 2023, Royalty Pharma began repurchasing its Class A ordinary shares and repurchased approximately four million shares for $134 million.
  • The weighted-average diluted Class A ordinary shares outstanding for the second quarter of 2023 was 606 million as compared to 607 million for the first quarter of 2023.

Long-Term Psoriatic Arthritis Data for AbbVie's Skyrizi Likely to Impact Future IL-23 Preference, Spherix Global Insights Reports

Retrieved on: 
Wednesday, December 21, 2022
Patient, Gastroenterology, HCP, Dermatology, Nephrology, ACR20, Rheumatology, Novartis, JAK, Janssen, Neck, Dactylitis, News, Psoriatic arthritis, Keepsake, IL-23, AbbVie, TNF, PASI, Ophthalmology, Skin, Neurology, Pharmaceutical industry, Guselkumab, Risankizumab, Upadacitinib

EXTON, Pa., Dec. 21, 2022 /PRNewswire/ -- Spherix Global Insights, a leading provider of market research, business intelligence, and advisory services to the global life sciences industry, has been tracking the evolution of the US psoriatic arthritis (PsA) market for seven years, including the uptake and impact of various market entrants.

Key Points: 
  • RealTime Dynamix™ is an independent study service by Spherix Global Insights that provides strategic guidance through quarterly or semiannual reports.
  • Spherix Global Insights is a leading provider of market research, business intelligence and advisory services to the global life sciences industry.
  • A trusted advisor and industry thought leader, Spherix Global Insights provides specialized market expertise in six (6) focused therapeutic areas including: dermatology, gastroenterology, nephrology, neurology, rheumatology and ophthalmology.
  • To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn and Twitter .

The Psoriatic Arthritis Landscape Continues to Evolve as New Launches Alter Dynamics in Both US and EU Markets, Spherix Reports

Retrieved on: 
Thursday, October 13, 2022
Psoriatic arthritis, Physician, Upadacitinib, MOA, Growth, Need for Speed, AbbVie, EMA, UCB, Pfizer, IL-23, Patient, Rheumatology, Kwaku Amoa-Awuah, TNF, Medicare, Secukinumab, Novartis, Safety, HCP, Adalimumab, Janssen, FDA, Nephrology, JAK, Pharmaceutical industry, Retail, Risankizumab, Guselkumab

EXTON, Pa., Oct. 13, 2022 /PRNewswire/ -- TNF inhibitors continue to be the mainstay for treating psoriatic arthritis (PsA), largely driven by the gold standards, etanercept and adalimumab. However, the recent entrance of IL-23 inhibitors (Janssen's Tremfya and AbbVie's Skyrizi) have an opportunity to impact a once relatively stable market.

Key Points: 
  • However, the recent entrance of IL-23 inhibitors (Janssen's Tremfya and AbbVie's Skyrizi) have an opportunity to impact a once relatively stable market.
  • Surveyed rheumatologists across both regions have reported newly approved treatments are experiencing growth within the indication.
  • Rheumatologists have expressed enthusiasm for the dual IL-17 A/F inhibition, which will likely help Bimzelx stand out from in-class competitors.
  • As the treatment landscape continues to evolve, it will be of paramount importance to track the perceptions and natural positions of AMOAs in the post-TNF setting.

Novartis' Cosentyx and Eli Lilly's Taltz Remain Leaders in US and EU5 Psoriatic Arthritis Switching Market, but Janssen's Tremfya and AbbVie's Skyrizi Are Picking Up Steam, Spherix Reports

Retrieved on: 
Tuesday, June 14, 2022
Psoriatic arthritis, IL-23, Guselkumab, Ustekinumab, Certolizumab pegol, Pfizer, Tofacitinib, Dermatology, TNF, Risankizumab, JAK, Patient, AbbVie, Need for Speed, Atopic dermatitis, Adoption, Rheumatology, Culture, Janssen, Neck, Nephrology, UCB, Medical device, Pharmaceutical industry, Secukinumab, Ixekizumab, Upadacitinib, State

EXTON, Pa., June 14, 2022 /PRNewswire/ -- Spherix Global Insights, a leading market intelligence firm specializing in immunology-based research and insights, recently published several large-scale patient audits focused on psoriatic arthritis (PsA) patients recently switched from one advanced systemic agent to another. Rheumatologists and dermatologists in the United States report that just under one-in-three of their biologic/small molecule-treated PsA patients are switched from one brand to another each year, while those from the EU5 report the same for approximately one-in-four patients.

Key Points: 
  • As such, nearly equal parts of patients were switched between TNFs as were switched from a TNF to an AMOA.
  • Conversely, those treated by a dermatologist (n=510 patients) are substantially less likely to be treated with back-to-back TNFs.
  • However, dermatologists are prescribing Tremfya and Skyrizi to nearly double the amount of later-line PsA patients than their rheumatology counterparts.
  • Counter to brand patterns revealed by the rheumatology audit, US dermatologists favor Taltz over Cosentyx, while Skyrizi and Tremfya switches are neck and neck.

Royalty Pharma Declares Second Quarter 2022 Dividend

Retrieved on: 
Monday, April 18, 2022
Johnson, Nasdaq, Royalty Pharma, AbbVie, GLOBE, Guselkumab, Holding company, Fine chemical

NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share.

Key Points: 
  • NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share.
  • The dividend will be paid on June 15, 2022, to shareholders of record at the close of business on May 20, 2022.
  • Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.

Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022

Retrieved on: 
Wednesday, April 13, 2022
Johnson, Nasdaq, Royalty Pharma, Guselkumab, AbbVie, GLOBE, Webcast, Fine chemical

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S. financial markets open.

Key Points: 
  • NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S. financial markets open.
  • The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
  • The conference call can be accessed live over the phone for U.S. callers by dialing (833) 519-1253 or for international callers by dialing +1 (914) 800-3826.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.

Royalty Pharma to Present at Cowen's 42nd Annual Health Care Conference

Retrieved on: 
Thursday, March 3, 2022
Conference, Royalty Pharma, Johnson, AbbVie, Nasdaq, GLOBE, Guselkumab, Fine chemical

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowens 42nd Annual Health Care Conference on March 8, 2022 at 11:10 a.m.

Key Points: 
  • NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowens 42nd Annual Health Care Conference on March 8, 2022 at 11:10 a.m.
  • The webcast will be accessible from Royalty Pharmas Events page at https://www.royaltypharma.com/investors/news-and-events/events .
  • The webcast will also be archived for a minimum of thirty days.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.

Royalty Pharma Announces Inaugural Investor Day

Retrieved on: 
Wednesday, February 16, 2022
Royalty Pharma, Pharma, Webcast, Johnson, Guselkumab, Nasdaq, AbbVie, GLOBE, Fine chemical

NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an inaugural Investor Day in New York City on Tuesday, May 17, 2022, starting at 8:30 a.m.

Key Points: 
  • NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an inaugural Investor Day in New York City on Tuesday, May 17, 2022, starting at 8:30 a.m.
  • Royalty Pharma senior executives will present on the outlook for royalty funding in life sciences, the companys capital deployment opportunities and long-term growth targets.
  • Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.

2022 Update Bulletin on Psoriasis - ResearchAndMarkets.com

Retrieved on: 
Friday, February 11, 2022
Hospitals, General Health, Health, Other Health, Janssen Biotech, Phase, Lists of people executed in the United States, UCB, Psoriasis, Bimekizumab, Safety, KOL, Public relations, Pharmaceutical industry, EU, Guselkumab

The "Psoriasis: Update Bulletin" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Psoriasis: Update Bulletin" newsletter has been added to ResearchAndMarkets.com's offering.
  • This edition presents key opinion leader (KOL) views on recent developments in the Psoriasis market.
  • If approved, where do KOLs think bimekizumab will be positioned within the psoriasis treatment paradigm?
  • How does Tremfya compare with other treatments for psoriasis, and will Janssen Biotech need to take any additional steps to help differentiate it?